Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a Phase III study for its S1P receptor modulator Zeposia (ozanimod) in patients with moderate-to-severe active Crohn’s disease (CD) did not meet its primary endpoint of clinical remission at week 12. The trial’s outcome means that Zeposia joins a number of other S1P modulator candidates that have not demonstrated efficacy in late-stage development for CD.
Despite the setback, Bristol Myers Squibb intends to conduct a comprehensive evaluation of the trial data. The company also reported that no new safety concerns were identified in the study, indicating that the drug’s safety profile remains consistent with previous findings.- Flcube.com
